PAR PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM, and what generic alternatives to PAR PHARM drugs are available?
PAR PHARM has ninety-nine approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and forty-nine supplementary protection certificates in fourteen countries.
Summary for PAR PHARM
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 59 |
| Ingredients: | 58 |
| NDAs: | 99 |
| Patent Litigation for PAR PHARM: | See patent lawsuits for PAR PHARM |
| PTAB Cases with PAR PHARM as petitioner: | See PTAB cases with PAR PHARM as petitioner |
Drugs and US Patents for PAR PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm | SUMYCIN | tetracycline hydrochloride | SUSPENSION;ORAL | 060400-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm Inc | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | CAPSULE;ORAL | 207199-003 | Mar 14, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm | CLOZAPINE | clozapine | TABLET;ORAL | 075162-001 | Apr 26, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm Inc | AMBRISENTAN | ambrisentan | TABLET;ORAL | 209509-002 | Apr 10, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm | HALOPERIDOL | haloperidol | TABLET;ORAL | 071328-001 | Jul 20, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm | FENTANYL CITRATE | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 077312-005 | Oct 30, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm | OXYMORPHONE HYDROCHLORIDE | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200792-004 | Oct 24, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PAR PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for PAR PHARM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006115626 | ⤷ Sign Up |
| Canada | 2605413 | ⤷ Sign Up |
| China | 101163679 | ⤷ Sign Up |
| Japan | 5378788 | ⤷ Sign Up |
| European Patent Office | 1948613 | ⤷ Sign Up |
| Japan | 2008538560 | ⤷ Sign Up |
| Australia | 2006240490 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PAR PHARM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0296560 | SPC/GB97/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
| 2101777 | 93081 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
| 2330892 | CR 2016 00062 | Denmark | ⤷ Sign Up | PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REG. NO/DATE: EU/1/15/1062/001-004 20151201 |
| 2330892 | 122016000107 | Germany | ⤷ Sign Up | PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 20151127 |
| 2330892 | 93351 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1062 |
| 0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 0502314 | SPC/GB02/037 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
